title: [Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide].
abstract: METHODS
  A 75-year-old woman with histologically confirmed liver metastases from an undiagnosed primary tumor was admitted for further diagnosis and treatment. She had no symptoms and was in a very good general condition. The physical examination was unremarkable.
  
  
  METHODS
  The liver enzymes GOT and GPT were slightly elevated. The carcinoembryonic antigen (CEA) and the erythrocyte sedimentation rate (ESR) were markedly raised. Repeat analysis of the liver biopsies revealed a carcinoma with neuroendocrine differentiation (carcinoid).
  
  
  METHODS
  Chemoembolization of the advanced liver metastases was undertaken. Subsequently the breast tumor was resected. Histological analysis revealed a mammary carcinoma with neuroendocrine differentiation. Postoperative radiotherapy to the breast was instituted and she was started on tamoxifen (30 mg daily). But despite repeat chemoembolization the liver metastases continued to grow. Administration of octreotide, a somatostatin analogue, was begun (200 micrograms twice daily). There were no side effects; the tumor markers showed definite reduction and scintigraphy demonstrated almost complete regression. Computed tomography indicated a dissociated response of the liver metastases to the treatment (some got smaller, one had grown and several new ones had appeared).
  
  
  CONCLUSIONS
  Combined tamoxifen and octreotide treatment of a metastasizing carcinoma of the breast with neuroendocrine differentiation may give effective palliation.
authors: Klinik für Strahlentherapie und Onkologie, Johann-Wolfgang-Goethe-Universität Frankfurt/Main.
authors: H C
authors: HC
authors: Rischke
authors: E
authors: E
authors: Staib-Sebler
authors: S
authors: S
authors: Mose
authors: S W
authors: SW
authors: Adams
authors: G
authors: G
authors: Herrmann
authors: H D
authors: HD
authors: Böttcher
authors: M
authors: M
authors: Lorenz
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D016461:Chemoembolization, Therapeutic / Q000379:methods; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary*; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis* / Q000188:drug therapy; D015282:Octreotide / Q000008:administration & dosage; D010166:Palliative Care; D013629:Tamoxifen / Q000008:administration & dosage
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D013629:Tamoxifen; D015282:Octreotide